# enU Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enu-pharma

- Industry: Biotechnology
- Headquarters: Sapporo-shi, Japan
- Website: www.enupharma.com
- Total disclosed funding: $2.6M
- Latest round: Seed (Jan 31, 2025)
- Investors on record: 4

## About

Founded in 2019 and based in Sapporo, Japan, enU Pharma, Inc. operates as a company that develops antibody drugs targeting glycopeptides for drug discovery, focusing on treatments for diseases using various scientific methods and technologies. In January 2025, enU Pharma, Inc. raised JPY 400 million in seed funding from Kyoto University Innovation Capital, Taiho Innovations, LLC., DG Incubation, and Hokkaido Kyoso Partners. 

enU Pharma, Inc. specializes in the development of innovative monoclonal antibody (mAb) therapeutics, leveraging advanced glycan analysis technology and antigen presentation methods rooted in research led by Professor Shinichiro Nishimura at Hokkaido University. Their core product offerings focus on the creation of highly selective antibodies targeting glycopeptides to provide new therapeutic options for diseases lacking effective treatments. The company can produce a continuous supply of these antibodies, addressing unmet medical needs in oncology and autoimmune diseases. Their products target pharmaceutical companies and research institutions in North America and Europe, where demand for novel therapeutic agents is substantial.

enU Pharma, Inc. operates on a transactional model that encompasses partnerships with pharmaceutical companies and research organizations, facilitating the development and commercialization of monoclonal antibody products. The company engages in collaborative agreements that involve shared research funding and milestone payments tied to specific development phases. 

enU Pharma, Inc. plans to use the JPY 400 million raised in January 2025 to accelerate the development of glycopeptide-targeted antibody drugs specifically for treating cancer, autoimmune diseases, and dementia. The company aims to introduce new products targeting these conditions and expand its market presence in North America and Europe by mid-2025. This strategic growth initiative is designed to enhance its portfolio and respond to the high demand for effective medical treatments.

## Funding rounds

- Seed, Jan 31, 2025, $2.6M — Kyoto University Innovation Capital, DG Incubation, Hokkaido Kyoso Partners, Taiho Innovations, LLC.

## Investors

- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed
- DG Incubation (https://capitalatlas.ai/funds/dg-incubation) — Seed
- Hokkaido Kyoso Partners (https://capitalatlas.ai/funds/hokkaido-kyoso-partners) — Seed
- Taiho Innovations, LLC. — Seed